TP53 and acute myeloid leukemia: The lack of unique features of mutation in TP53 gene between t-MN and de novo diseases indicates that cytotoxic therapy does not cause genome-wide damage in TP53; rather the genetic insult to TP53 gene is similar in MDS/AML either secondary to cytotoxic therapy or occurring de novo.